Long-Standing Remission After Tildrakizumab Treatment in a Case of Refractory Type I Pityriasis Rubra Pilaris in a Breast Cancer Patient

Vito Di Lernia,Francesca Peccerillo

DOI: https://doi.org/10.2147/ccid.s483166

2024-10-16

Clinical Cosmetic and Investigational Dermatology

Abstract:Vito Di Lernia, Francesca Peccerillo Dermatology Unit, Azienda Unità Sanitaria Locale- IRCCS di Reggio Emilia, Reggio Emilia, Italy Correspondence: Vito Di Lernia, Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento 80, Reggio Emilia, 42123, Italy, Tel +39 522 296873, Email Pityriasis rubra pilaris (PRP) is a rare chronic inflammatory skin disease characterised by follicular keratotic papules and perifollicular erythema coalescing into orange-red scaly plaques, and palmoplantar keratoderma. Characteristic islands of sparing are usually observed. A standardised therapeutic approach is lacking owing to the infrequent occurrence of this disease. However, anti-interleukin (IL)-17 and anti-IL-23 therapies have recently emerged as effective therapies in patients affected by PRP, with improvements in severity scores, change in severity of erythema, scaling, and thickness of lesions. Here, we report a 43-year old, female breast cancer who developed severe refractory PRP, which greatly impacted her quality of life. The patient experienced a marked improvement after treatment with tildrakizumab. Treatment was stopped after one year, and the three-year follow-up did not show relapse. In conclusion, 52- week treatment with tildrakizumab, an IL-23 antagonist, proved to be a favourable treatment option for PRP, leading to good patient adherence, improvement in quality of life, and long-term follow-up without relapse. Keywords: pityriasis rubra pilaris, treatment, tildrakizumab, breast cancer Pityriasis rubra pilaris (PRP) is a rare, chronic, papulosquamous inflammatory dermatosis whose pathogenesis remains unclear. It is clinically characterised by keratotic follicular papules, well-demarcated salmon-coloured scaly plaques interspersed with distinct islands of unaffected skin, and palmoplantar keratoderma. 1 Both sexes and all ages, including children, are affected, with two common peaks: the first in childhood (1–10 years of age) and the second in adulthood (50–60 years of age). According to Griffiths' classification, based on the age of onset, clinical features, prognosis, and other associated aspects, five types of PRP were distinguished. 1 The disease duration may vary from month to year. Treatment is a major therapeutic challenge owing to the lack of clinical evidence. A 43-year-old patient receiving tamoxifen for adjuvant treatment of oestrogen-positive breast cancer diagnosed 4 years ago presented with widespread, scaly, red-orange plaques showing keratotic follicular papules on the scalp, chest, back, and limbs. Skin lesions showed extensive coalescence with circumscribed islands sparing the trunk and the upper and lower extremities (Figure 1a and b). Mild palmoplantar keratoderma was observed. The laboratory test results did not reveal any significant abnormalities. Family history of psoriasis and PRP were negative. Skin biopsy revealed alternating orthokeratosis and parakeratosis, psoriasiform acanthosis, follicular plugging with parakeratosis at the edges of the follicular orifice, and marked acantholysis in multiple areas. The immunofluorescence analysis yielded negative results. Based on clinical and histopathological findings, the patient was diagnosed with type 1 PRP. Prior systemic treatments included oral steroids (prednisone 0.5 mg/kg/day tapered over 6 weeks) and cyclosporine (3 mg/kg/day for 4 months) without any noticeable therapeutic effect. UVB 311 nm phototherapy (24 exposures) was also performed without any clinical improvement. The Total Body Surface Area (BSA) involved was approximately 40%, with a significant impact on the patient's quality of life (DLQI: 20) and daily functioning. Owing to the disease severity, persistent itchy symptoms, lack of efficacy of previous therapies, and cancer history, treatment with tildrakizumab was initiated. The drug was administered subcutaneously at a dose of 100 mg (weeks 0, 4, and 12-weekly thereafter). The treatment was continued at a 12-week subcutaneous dose of 100 mg. Figure 1 ( a and b ). Extensive skin involvement with small islands of sparing on the trunk and lower extremities before tildrakizumab treatment. Significant improvement was observed after 16 weeks, with residual mild palmar hyperkeratosis and erythematous skin patches in the pectoral region (Figure 2a and b). The BSA and DLQI ratings were 5% and 4, respectively. At week 28, only scattered patches were observed in the pectoral region, with BSA 4% and DLQI 4.- At week 40, a sustained therapeutic effect was observed and no adverse effects were reported. The treatment was stopped after 52 weeks. A three-year follow-up did not reveal relapse of PRP or any adverse effects. The oncologic follow-up results were negative. Figure 2 ( a -Abstract Truncated-

dermatology